TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers, has reported promising preclinical results for its lead therapeutic candidate, TTX-MC138, in a model of breast cancer bone metastasis. The findings, published in a peer-reviewed article in the journal Cancers, highlight the drug's ability to accumulate in metastatic bone lesions and produce significant survival benefits, offering hope for a challenging clinical scenario.
The study, which focused on the role of microRNA-10b (miR-10b) in metastasis, demonstrated that systemic administration of TTX-MC138 led to its accumulation in metastatic bone lesions. This accumulation resulted in reduced expression of miR-10b, a known driver of metastasis, and a corresponding increase in the expression of the downstream tumor-suppressor target HOXD10. More importantly, the treatment produced significant survival benefits compared to control groups, with repeated dosing being well tolerated and showing no observed systemic toxicity.
These findings further validate TransCode's approach of inhibiting miR-10b using its proprietary oligonucleotide nanotechnology. The technology is designed to specifically target and silence miR-10b, which is overexpressed in many metastatic tumors and serves as a well-documented biomarker of metastasis. By inhibiting this microRNA, the therapy aims to disrupt the metastatic process, potentially preventing the spread of cancer to vital organs.
The significance of these results extends beyond breast cancer bone metastasis. The study suggests that the therapeutic approach may have potential applicability across additional metastatic disease settings, addressing a major unmet medical need. Bone metastasis is a common complication in advanced cancers, including breast, prostate, and lung cancers, and is associated with significant morbidity and reduced quality of life. Current treatment options are often limited, and the prognosis for patients with bone metastasis remains poor.
For leaders in the business and technology sectors, this development underscores the potential of RNA-based therapeutics to revolutionize cancer treatment. The precision targeting of microRNAs involved in metastasis represents a novel mechanism of action that could complement existing immunotherapies and chemotherapies. TransCode's continued progress in clinical development could lead to new treatment paradigms for metastatic cancers, which are responsible for the majority of cancer-related deaths.
The results of this preclinical study are a critical step forward for TransCode as it advances TTX-MC138 toward clinical trials. The company's pipeline includes other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells, positioning it as a key player in the emerging field of RNA-based oncology.
For more information, the full press release is available at https://ibn.fm/E6gbq. Additional updates and news regarding TransCode Therapeutics can be found in the company's newsroom at https://ibn.fm/RNAZ.
